Dengue Management Guidelines

Initial Assessment and Management

The Centers for Disease Control and Prevention recommends that all patients with clinically suspected dengue should receive appropriate management to monitor for shock and reduce the risk for complications resulting from plasma leakage and organ damage without waiting for diagnostic test results 1
Patients should be immediately classified into one of three categories: dengue without warning signs, dengue with warning signs, or severe dengue, as this determines the entire management approach 2
Warning signs to identify immediately include high hematocrit with rapidly falling platelet count, severe abdominal pain, persistent vomiting, lethargy or restlessness, mucosal bleeding, and cold, clammy extremities (early shock) 3

Aggressive oral hydration with target fluid intake of 2,500-3,000 mL daily using any locally available fluids is recommended for patients with dengue without warning signs 3
Avoid soft drinks due to high osmolality 3
For patients with severe dengue or dengue shock syndrome, administer 20 mL/kg of isotonic crystalloid as a rapid bolus over 5-10 minutes with immediate reassessment after each bolus 3
Reassess immediately after the first bolus for signs of improvement, and if shock persists, repeat crystalloid boluses up to a total of 40-60 mL/kg in the first hour before escalating therapy 3

Blood transfusion may be necessary for significant bleeding, with a target hemoglobin >10 g/dL if ScvO2 <70% 3
Prophylactic platelet transfusion is not recommended, but may be considered in certain cases 3
After initial shock reversal, fluid removal may be necessary, as evidence shows aggressive shock management followed by judicious fluid removal decreased pediatric ICU mortality from 16.6% to 6.3% 3

Pregnant women should be tested by NAAT for both dengue and Zika virus, regardless of outbreak patterns, due to risk of maternal death, hemorrhage, preeclampsia, and vertical transmission 1
Acetaminophen remains the safest analgesic option for pregnant women 2
Hospitalization is recommended for all pregnant women with confirmed or suspected dengue 2

Delaying fluid resuscitation in established dengue shock syndrome significantly increases mortality, as cardiovascular collapse may rapidly follow once hypotension occurs 3
Administering excessive fluid boluses in patients without shock leads to fluid overload and respiratory complications 3
Failing to recognize the critical phase (typically days 3-7 of illness) when plasma leakage can rapidly progress to shock 3
Continuing aggressive fluid resuscitation once signs of fluid overload appear instead of switching to inotropic support 3
Using aspirin or NSAIDs, which worsen bleeding tendencies 3

For patients presenting within 7 days of symptom onset, obtain a dengue PCR/NAAT on serum because viral RNA remains detectable for approximately 4–6 days after onset, making this the preferred diagnostic modality according to CDC recommendations. 4
When symptom duration exceeds 7 days or PCR testing is unavailable, perform an IgM capture ELISA as the primary serologic test, as advised by the CDC. 4
Record a complete flavivirus vaccination history (e.g., yellow fever, Japanese encephalitis, Zika) before interpreting serologic results, since prior vaccination can cause cross‑reactive IgM false‑positives, per CDC guidance. 4

Conduct daily urine output assessment and repeat urinalysis to detect worsening hematuria or new proteinuria, both of which have been shown to correlate with increased disease severity in dengue patients (Journal of Infection). 5

In pregnant individuals, perform simultaneous dengue and Zika NAAT testing irrespective of current outbreak patterns, because co‑infection poses heightened risks of maternal hemorrhage, severe disease, and vertical transmission, as recommended by the CDC. 4